Aclacinomycin A (ACM) wurde zur Behandlung rezidivierter oder primär chemotherapieresistenter akuter Leukämien eingesetzt. Die Dosierung betmg 25 mg/m2 i.v. täglich an 7 aufeinanderfolgenden Tagen. Von den 21 behandelten Patienten sind 17 auswertbar, 2 mit akuter lymphatischer und 15 mit akuter myeloischer Leukämie. Bei den akuten myeloischen Leukämien sind 2 komplette und eine partielle Remission erzielt worden. Die partielle Rückbildung der leukämischen Knochenmarkinfiltration ist bei einer Kranken mit primärer Resistenz gegen Daunorubicin und Adriamycin beobachtet worden. Bei den Patienten mit akuter lymphatischer Leukämie wurde keine Remission erzielt.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.